Fares Kano
Research Subjects
Research Interests
Fares Kano has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Carlo-Federico Fichera
Department of Cardiology, County Hospital Loerrach, Spitalstraße 25, Loerrach, 79539, Germany.
1 shared publication - Christin Fichera
Faculty of Medicine, Justus-Liebig University Giessen, Ludwigstraße 23, 35390 Giessen, Germany
1 shared publication - Dieter Fischer
Leibniz-Institut für Polymerforschung Dresden e.V., 01069 Dresden, Germany
1 shared publication - Dimitar Divchev
Philipps University of Marburg, Cardiology, Angiology, Internal Medicine and Intensive Care Unit, Cardiac Arrest Marburg , Marburg , Germany
1 shared publication - Felix Ausbuettel
Department of Cardiology, University Hospital Marburg Philipps University Marburg Marburg Germany
1 shared publication - Nikolaos Patsalis
Department of Cardiology, Angiology, and Intensive Care Medicine, Philipps-Universität Marburg, Baldingerstraße, 35043 Marburg, Germany
1 shared publication
Latest Publications
- Open Access
- 22 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2167
Predicting the Need for Intensive Care Unit Treatment After Successful Transcatheter Edge-to-Edge Mitral Valve Repair
Background/Objectives: Transcatheter edge-to-edge mitral valve repair (M-TEER) has emerged as an efficacious treatment modality among patients at high perioperative risk. Given the steady increase in procedures and the limited capacity for intensive care, there is a need to identify patients at high risk for postinterventional intensive care. Methods: All patients who underwent M-TEER between 2014 and 2023 were investigated. The intensive care unit (ICU) stay ended when patients met all the following criteria: no further need for catecholamine support, no oxygen requirement > 6 L O2/min, no indication for renal replacement therapy, and no delirium or relevant bleeding. Uni- and multivariable logistic regression analyses were used to identify independent predictors of the need for ICU treatment. Results: In total, 33% of patients (62/183) had an indication for ICU treatment after M-TEER. Patients with an indication for ICU treatment had significantly lower survival rates three years after M-TEER (37.4% [23/62] vs. 61.6% [75/121], p < 0.001) than patients without an ICU indication. A EuroSCORE II of >10% (OR 2.6, 95% CI 1.3–5.4, p = 0.006), a MitraScore of >3 (OR 2.5, 95% CI 1.2–5.2, p = 0.02), and a hospital stay of >5 days before M-TEER (OR 3.2, 95% CI 1.6–6.4, p < 0.001) were independently associated with the need for ICU treatment. Conclusions: One-third of the patients were indicated for ICU treatment, which was associated with a high mortality rate. On the basis of these predictors of required ICU care, tailored treatment strategies can be developed to improve treatment outcomes.
- 22 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2167
Open AccessPredicting the Need for Intensive Care Unit Treatment After Successful Transcatheter Edge-to-Edge Mitral Valve Repair
Background/Objectives: Transcatheter edge-to-edge mitral valve repair (M-TEER) has emerged as an efficacious treatment modality among patients at high perioperative risk. Given the steady increase in procedures and the limited capacity for intensive care, there is a need to identify patients at high risk for postinterventional intensive care. Methods: All patients who underwent M-TEER between 2014 and 2023 were investigated. The intensive care unit (ICU) stay ended when patients met all the following criteria: no further need for catecholamine support, no oxygen requirement > 6 L O2/min, no indication for renal replacement therapy, and no delirium or relevant bleeding. Uni- and multivariable logistic regression analyses were used to identify independent predictors of the need for ICU treatment. Results: In total, 33% of patients (62/183) had an indication for ICU treatment after M-TEER. Patients with an indication for ICU treatment had significantly lower survival rates three years after M-TEER (37.4% [23/62] vs. 61.6% [75/121], p < 0.001) than patients without an ICU indication. A EuroSCORE II of >10% (OR 2.6, 95% CI 1.3–5.4, p = 0.006), a MitraScore of >3 (OR 2.5, 95% CI 1.2–5.2, p = 0.02), and a hospital stay of >5 days before M-TEER (OR 3.2, 95% CI 1.6–6.4, p < 0.001) were independently associated with the need for ICU treatment. Conclusions: One-third of the patients were indicated for ICU treatment, which was associated with a high mortality rate. On the basis of these predictors of required ICU care, tailored treatment strategies can be developed to improve treatment outcomes.